The estimated Net Worth of Kevin Haas is at least $11.4 Tisíc dollars as of 1 February 2019. Kevin Haas owns over 204 units of Aravive Inc stock worth over $437 and over the last 7 years Kevin sold ARAV stock worth over $10,951.
Sign up
Kevin Haas ARAV stock SEC Form 4 insiders trading
Kevin has made over 5 trades of the Aravive Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Kevin sold 204 units of ARAV stock worth $845 on 1 February 2019.
The largest trade Kevin's ever made was selling 1,599 units of Aravive Inc stock on 8 February 2018 worth over $2,878. On average, Kevin trades about 546 units every 51 days since 2017. As of 1 February 2019 Kevin still owns at least 10,933 units of Aravive Inc stock.
You can see the complete history of Kevin Haas stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kevin Haas's mailing address?
Kevin's mailing address filed with the SEC is 1020 Marsh Rd, Menlo Park, CA 94025, USA.
Insiders trading at Aravive Inc
Over the last 6 years, insiders at Aravive Inc have traded over $107,045 worth of Aravive Inc stock and bought 151,333 units worth $1,102,898 . The most active insiders traders include Srinivas Akkaraju, Fredric N Eshelman Ventures... a Shahzad Malik. On average, Aravive Inc executives and independent directors trade stock every 75 days with the average trade being worth of $11,962. The most recent stock trade was executed by Fredric N Eshelman Ventures... on 1 April 2022, trading 4,545,455 units of ARAV stock currently worth $181,818.
What does Aravive Inc do?
versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.
What does Aravive Inc's logo look like?
Complete history of Kevin Haas stock trades at Aravive Inc
Aravive Inc executives and stock owners
Aravive Inc executives and other stock owners filed with the SEC include:
-
Gail McIntyre,
President, Chief Executive Officer, Director -
Vinay Shah,
Chief Financial Officer -
Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.,
Pres, CEO & Director -
Dr. Reshma Rangwala M.D., Ph.D.,
Chief Medical Officer -
Amato Giaccia,
Independent Director -
Raymond Tabibiazar,
Independent Director -
Eric Zhang,
Independent Director -
Dr. Fredric N. Eshelman Pharm.D.,
Exec. Chairman -
Mike Zanoni,
IR Contact Officer -
Michael Rogers,
Director -
Reshma Rangwala,
Chief Medical Officer -
Fredric Eshelman,
Independent Chairman of the Board -
Kenneth L. Guernsey,
Sec. -
Dr. Randy L. Anderson,
Sr. VP of Data Sciences -
Joseph T. Schepers,
VP of Investor Relations -
Dr. Joshua Silverman Ph.D.,
Co-Founder -
Dr. Jeffrey L. Cleland,
Co-Founder -
Maria Carolina Petrini,
Chief Commercial Officer -
Robert B. Geller,
Chief Medical Officer -
Leonard Scott Dove,
Chief Operating Officer -
Rekha Hemrajani,
-
Srinivas Akkaraju,
Director -
Jay Shepard,
President and CEO -
Kevin Haas,
VP, Finance and PAO -
Shahzad Malik,
Director -
Robert Hoffman,
Director -
Peter Tai Ching Ho,
Director -
John Hohneker,
Director -
Sigurd Kirk,
Director -
Rudy Howard,
Chief Financial Officer